A new absorbent reagent specifically designed for use in conjunction with immunodiagnostic assays is distinctively formulated to remove both IgG and Rheumatoid Factor (RF)-IgM molecules from human serum.

Developed by Binding SIte (San Diego, CA, USA), the “RF/IgG Absorbent Reagent” demonstrates outstanding performance characteristics in routine forms of use. In principle, the reagent effectively prevents these IgG and RF-IgM bodily components from nonspecific binding within the test sample. This eliminates certain interference effects found with some immunodiagnostic assays, which are looking to determine quantitatively human antigen-specific IgM immunoglobulin concentrations, as found in various diagnostic disease states. As such, the RF/IgG Absorbent Reagent serves to enhance overall specificity by reducing both the amount of false positive test results from native IgG components and the amount of false negative test results from native RF-IgM components.

Binding Site’s new RF/IgG Absorbent Reagent is available as a ready-to-use, liquid stable product and is offered in a number of convenient, operator-oriented packaging configurations, including bulk-sized formats.

Related Links:
Binding Site